Polymeric nanoparticles, especially those derived from PLGA (poly(lactic-co-glycolic acid)), have been used to prepare long-acting formulations of GLP-1 that can extend the release period to weeks with a single dose, reducing injection frequency and improving patient adherence [33]
As a team that specializes exclusively in this field, we've seen the good, the bad, and the downright dangerous
Plus, it features Gingever, a clinically studied potent ginger extract, to help relieve occasional nauseaallowing you to focus on your goals without a fear of the bathroom getting in the way.*
Market Segmentation Global Glucagon-Like Peptide-1 Agonists Market Size, Share & Industry Analysis, By Product Type (Short-Acting GLP-1 Agonists, Long-Acting GLP-1 Agonists), By Route of Administration (Injectable, Oral), By Application (Type 2 Diabetes, Obesity Management, Cardiovascular Disease Management), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), Analysis and Forecast 20262035 Global Glucagon-Like Peptide-1 Agonists Market Size & Statistics The Market size of global glucagon-like peptide-1 agonists was estimated to be worth USD 46.18 Billion in 2025
March 2024
4 Myth : All GLP-1 weight-loss drugs are the same
